This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Macular Degeneration  • Alert me on articles by topic  Social Bookmarking   What's this?

AREDS Report No. 11

Age-Related Eye Disease Study Research Group^*

Arch Ophthalmol. 2003;121:1621-1624.

Objective  To estimate the potential public health impact of the findings of the Age-Related Eye Disease Study (AREDS) on reducing the number of persons developing advanced age-related macular degeneration (AMD) during the next 5 years in the United States.

Methods  The AREDS clinical trial provides estimates of AMD progression rates and of reduction in risk of developing advanced AMD when a high-dose nutritional supplement of antioxidants and zinc is used. These results are applied to estimates of the US population at risk, to estimate the number of people who would potentially avoid advanced AMD during 5 years if those at risk were to take a supplement such as that used in AREDS.

Results  An estimated 8 million persons at least 55 years old in the United States have monocular or binocular intermediate AMD or monocular advanced AMD. They are considered to be at high risk for advanced AMD and are those for whom the AREDS formulation should be considered. Of these people, 1.3 million would develop advanced AMD if no treatment were given to reduce their risk. If all of these people at risk received supplements such as those used in AREDS, more than 300 000 (95% confidence interval, 158 000-487 000) of them would avoid advanced AMD and any associated vision loss during the next 5 years.

Conclusion  If people at high risk for advanced AMD received supplements such as those suggested by AREDS results, the potential impact on public health in the United States would be considerable during the next 5 years.

^*The Writing Team for the Age-Related Eye Disease Study (AREDS) Research Group consists of Neil M. Bressler, MD; Susan B. Bressler, MD; Nathan G. Congdon, MD; Frederick L. Ferris III, MD; David S. Friedman, MD; Ronald Klein, MD; Anne S. Lindblad, PhD; Roy C. Milton, PhD; and Johanna M. Seddon, MD. A complete list of the members of the AREDS Research Group appears in Arch Ophthalmol 2001;119:1434. The Writing Team for this report and the AREDS investigators have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

AREDS—Two Years Later
Lee M. Jampol
Arch Ophthalmol. 2003;121(11):1634-1636.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials
Suner et al.
IOVS 2009;50:3629-3635.
ABSTRACT | FULL TEXT  

Quantitative Subanalysis of Cystoid Spaces and Outer Nuclear Layer Using Optical Coherence Tomography in Age-Related Macular Degeneration
Kashani et al.
IOVS 2009;50:3366-3373.
ABSTRACT | FULL TEXT  

Effects of Dioxin on Vascular Endothelial Growth Factor (VEGF) Production in the Retina Associated with Choroidal Neovascularization
Takeuchi et al.
IOVS 2009;50:3410-3416.
ABSTRACT | FULL TEXT  

Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study
Schmid-Kubista et al.
Br J Ophthalmol 2009;93:914-919.
ABSTRACT | FULL TEXT  

Visualization of Sub-retinal Pigment Epithelium Morphologies of Exudative Macular Diseases by High-Penetration Optical Coherence Tomography
Yasuno et al.
IOVS 2009;50:405-413.
ABSTRACT | FULL TEXT  

A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
Arias et al.
Br J Ophthalmol 2008;92:1636-1641.
ABSTRACT | FULL TEXT  

Quantitative Optical Coherence Tomography Findings in Various Subtypes of Neovascular Age-Related Macular Degeneration
Liakopoulos et al.
IOVS 2008;49:5048-5054.
ABSTRACT | FULL TEXT  

Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration
Keane et al.
IOVS 2008;49:3115-3120.
ABSTRACT | FULL TEXT  

Age-Related Macular Degeneration
Jager et al.
NEJM 2008;358:2606-2617.
FULL TEXT  

Racial Differences and Other Risk Factors for Incidence and Progression of Age-Related Macular Degeneration: Salisbury Eye Evaluation (SEE) Project
Chang et al.
IOVS 2008;49:2395-2402.
ABSTRACT | FULL TEXT  

Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection
Baird et al.
Hum Mol Genet 2008;17:1299-1305.
ABSTRACT | FULL TEXT  

Foveal Cone-Photoreceptor Integrity in Aging Macula Disorder
Kanis et al.
IOVS 2008;49:2077-2081.
ABSTRACT | FULL TEXT  

Improved Vision-Related Function After Ranibizumab Treatment of Neovascular Age-Related Macular Degeneration: Results of a Randomized Clinical Trial
Chang et al.
Arch Ophthalmol 2007;125:1460-1469.
ABSTRACT | FULL TEXT  

Genetic Associations With Age-Related Macular Degeneration
Damian
JAMA 2007;298:1637-1637.
FULL TEXT  

Dietary carbohydrate and the progression of age-related macular degeneration: a prospective study from the Age-Related Eye Disease Study
Chiu et al.
Am. J. Clin. Nutr. 2007;86:1210-1218.
ABSTRACT | FULL TEXT  

Incident Choroidal Neovascularization in Fellow Eyes of Patients With Unilateral Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: SST Report No. 20 From the Submacular Surgery Trials Research Group
Submacular Surgery Trials Research Group
Arch Ophthalmol 2007;125:1323-1330.
ABSTRACT | FULL TEXT  

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Bashshur et al.
Arch Ophthalmol 2007;125:1357-1361.
ABSTRACT | FULL TEXT  

Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment
Bolz et al.
Br J Ophthalmol 2007;91:785-789.
ABSTRACT | FULL TEXT  

Scavenger Receptors for Oxidized Lipoprotein in Age-Related Macular Degeneration
Kamei et al.
IOVS 2007;48:1801-1807.
ABSTRACT | FULL TEXT  

Light Induces Programmed Cell Death by Activating Multiple Independent Proteases in a Cone Photoreceptor Cell Line
Kanan et al.
IOVS 2007;48:40-51.
ABSTRACT | FULL TEXT  

Potential value of antioxidant-rich foods in slowing age-related macular degeneration.
Mares
Arch Ophthalmol 2006;124:1339-1340.
FULL TEXT  

Hormone Therapy and Age-Related Macular Degeneration: The Women's Health Initiative Sight Exam Study
Haan et al.
Arch Ophthalmol 2006;124:988-992.
ABSTRACT | FULL TEXT  

A 76-year-old man with macular degeneration.
Arroyo
JAMA 2006;295:2394-2406.
FULL TEXT  

Progression of Age-Related Macular Degeneration: Prospective Assessment of C-Reactive Protein, Interleukin 6, and Other Cardiovascular Biomarkers
Seddon et al.
Arch Ophthalmol 2005;123:774-782.
ABSTRACT | FULL TEXT  

Nuclear Gene Expression Changes Due to Mitochondrial Dysfunction in ARPE-19 Cells: Implications for Age-Related Macular Degeneration
Miceli and Jazwinski
IOVS 2005;46:1765-1773.
ABSTRACT | FULL TEXT  

Photodynamic Therapy With Verteporfin: Observations on the Introduction of a New Treatment Into Clinical Practice
Schein et al.
Arch Ophthalmol 2005;123:58-63.
ABSTRACT | FULL TEXT  

Pegaptanib for Neovascular Age-Related Macular Degeneration
Gragoudas et al.
NEJM 2004;351:2805-2816.
ABSTRACT | FULL TEXT  

Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .
Bressler
JAMA 2004;291:1900-1901.
FULL TEXT  

Special Considerations in the Guidelines for High-Dose Vitamin Supplementation in Patients With Age-Related Macular Degeneration--Reply
Ferris and Milton
Arch Ophthalmol 2004;122:662-663.
FULL TEXT  

Age-related macular degeneration: armed against ARMD
Weir
CMAJ 2004;170:463-464.
FULL TEXT  

AREDS--Two Years Later
Jampol
Arch Ophthalmol 2003;121:1634-1636.
FULL TEXT